M&A Deal Summary

Apposite Capital Acquires i2a

On August 2, 2021, private equity firm Apposite Capital acquired medical products company i2a

Acquisition Highlights
  • This is Apposite Capital’s 3rd transaction in the Medical Products sector.
  • This is Apposite Capital’s 1st transaction in France.

M&A Deal Summary

Date 2021-08-02
Target i2a
Sector Medical Products
Buyer(s) Apposite Capital
Deal Type Buyout (LBO, MBO, MBI)
Advisor(s) Societe Generale Corporate & Investment Banking (Financial)
K&L Gates (Legal)

Target

i2a

Montpellier, France
i2a is a provider of instruments, software, and reagents for the clinical microbiology market in France. i2a specializes in offering automated solutions across the value chain of the bacteriology clinical testing market, including Antibiotic Sensitivity Testing which identifies bacterial resistance to antibiotics. i2a was founded in 1988 and is based in Montpellier, France.

Search 214,981 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Apposite Capital

London, United Kingdom

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2006
Size Small
Type Sector Focused
DESCRIPTION

Apposite Capital is a private investment firm focused on investing in growth companies in the healthcare sector. The Firm targets UK-based, revenue generating businesses and looks to invest £10 to £25 million over the life of an investment. Specific areas of interest include rehab services, primary and acute care companies, health related software solutions and IT, elderly and specialist healthcare services, medical products, and pharmaceuticals. Apposite Capital was established in 2006 and is based in London.


DEAL STATS #
Overall 15 of 19
Sector: Medical Products M&A 3 of 3
Type: Buyout (LBO, MBO, MBI) M&A Deals 7 of 10
Country: France M&A 1 of 1
Year: 2021 M&A 4 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-25 1MED

Agno, Switzerland

1MED is a specialist CRO that supports the commercialization of new medical technologies and products by providing regulatory strategy, clinical trial management, and quality assurance services across a broad range of therapeutic areas and product types. 1MED was founded in 2014 and is based in Agno, Switzerland.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-11 CrestOptics

Rome, Italy

CrestOptics manufactures high-end microscopy instruments under its own brand and as an original equipment manufacturer (OEM). The Company’s instrumentation can be integrated with other high-end imaging systems used in life science research to enhance detection and imaging performance. CrestOptics was formed in 2009 and is based in Rome, Italy.

Buy -